Egfr-tkis
Clinical Trials Overview
1 trials found
About Egfr-tkis
EGFR-TKIs (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors) are targeted therapy drugs that block the EGFR pathway, which is overexpressed in many colorectal cancers. These oral medications are typically used in combination with other treatments or as monotherapy for metastatic colorectal cancer.
Category
Other Medications
Brand Name
Cetuximab (Erbitux), Panitumumab (Vectibix), Erlotinib (Tarceva), Gefitinib (Iressa)
Mechanism
These drugs inhibit the tyrosine kinase activity of EGFR, blocking downstream signaling pathways that promote cancer cell growth and survival.
1
Total Trials
0
Recruiting
1
Active
0
Completed
600
Total Enrollment
1
Countries
NCT04584008
Not Applicable
Active
600 patients
This a prospective real-world navigation study using tumor DNA sequencing technology to sequence genes of previously treated and refractory gastrointestinal tumors, which are generally considered to be highly heterogeneous and complex, to screen pote...
China